Published in Br J Pharmacol on June 25, 2007
Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther (2010) 1.66
Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovasc Ther (2010) 1.39
Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol (1985) (2011) 1.18
Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol (2008) 1.15
Vitamin D improves the angiogenic properties of endothelial progenitor cells. Am J Physiol Cell Physiol (2012) 1.11
Gelatin in situ zymography on fixed, paraffin-embedded tissue: zinc and ethanol fixation preserve enzyme activity. J Histochem Cytochem (2009) 1.07
Notch modulates VEGF action in endothelial cells by inducing Matrix Metalloprotease activity. Vasc Cell (2011) 1.04
Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl)methylthiirane and its oxirane analogue. Biochemistry (2009) 1.04
Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.98
MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury. Am J Physiol Renal Physiol (2011) 0.97
Thoracic aortic dissection: are matrix metalloproteinases involved? Vascular (2009) 0.93
A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One (2012) 0.92
Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte. Br J Pharmacol (2007) 0.92
Ischemia induced peroxynitrite dependent modifications of cardiomyocyte MLC1 increases its degradation by MMP-2 leading to contractile dysfunction. J Cell Mol Med (2010) 0.91
Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor. Physiol Genomics (2009) 0.88
The impact of aging on cardiac extracellular matrix. Geroscience (2017) 0.87
TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J (2015) 0.87
Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.87
Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets (2013) 0.85
Intracellular Cleavage of the Cx43 C-Terminal Domain by Matrix-Metalloproteases: A Novel Contributor to Inflammation? Mediators Inflamm (2015) 0.85
Biocompatibility studies of low temperature nitrided and collagen-I coated AISI 316L austenitic stainless steel. J Mater Sci Mater Med (2013) 0.84
Matrix metalloproteinase 2 (MMP2) inhibition: DFT and QM/MM studies of the deprotonation-initialized ring-opening reaction of the sulfoxide analogue of SB-3CT. J Phys Chem B (2010) 0.84
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Rose hip and its constituent galactolipids confer cartilage protection by modulating cytokine, and chemokine expression. BMC Complement Altern Med (2011) 0.84
Cardiac capsaicin-sensitive sensory nerves regulate myocardial relaxation via S-nitrosylation of SERCA: role of peroxynitrite. Br J Pharmacol (2007) 0.84
Matrix metalloproteinase 9 expression: new regulatory elements. J Ocul Biol Dis Infor (2010) 0.83
Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension. Br J Pharmacol (2011) 0.83
Effects of sevoflurane preconditioning and postconditioning on rat myocardial stunning in ischemic reperfusion injury. J Zhejiang Univ Sci B (2010) 0.82
Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension. Redox Biol (2015) 0.82
Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart. Br J Pharmacol (2013) 0.81
Tetracyclines and pain. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.81
Unfractionated bone marrow cells attenuate paraquat-induced glomerular injury and acute renal failure by modulating the inflammatory response. Sci Rep (2016) 0.78
QM/MM Studies of the Matrix Metalloproteinase 2 (MMP2) Inhibition Mechanism of (S)-SB-3CT and its Oxirane Analogue. J Chem Theory Comput (2010) 0.78
Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine. Heart Fail Rev (2015) 0.78
A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice. Br J Pharmacol (2008) 0.77
Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function. J Cardiovasc Pharmacol (2009) 0.76
Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice. Interdiscip Toxicol (2013) 0.75
Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension. Arq Bras Cardiol (2015) 0.75
Assessment of control tissue for gene and protein expression studies: a comparison of three alternative lung sources. ScientificWorldJournal (2012) 0.75
Collagen-related biomarkers in severe sepsis: a big stretch? Crit Care (2009) 0.75
Prenatal nicotine increases matrix metalloproteinase 2 (MMP-2) expression in fetal guinea pig hearts. Reprod Sci (2011) 0.75
Remodeling of aorta extracellular matrix as a result of transient high oxygen exposure in newborn rats: implication for arterial rigidity and hypertension risk. PLoS One (2014) 0.75
Protective outcomes of low-dose doxycycline on renal function of Wistar rats subjected to acute ischemia/reperfusion injury. Biochim Biophys Acta (2017) 0.75
Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia. Biomed Res Int (2017) 0.75
Matrix metalloproteinases. J Biol Chem (1999) 12.08
Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev (2006) 7.92
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A (1962) 5.94
Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol (1989) 5.73
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev (2000) 5.33
Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest (2004) 4.97
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest (2002) 4.79
The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A (1990) 4.46
Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature (1989) 4.42
Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest (1996) 3.64
Families of zinc metalloproteases. FEBS Lett (1994) 3.40
Molecular and cellular mechanisms of myocardial stunning. Physiol Rev (1999) 3.16
Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem (1997) 3.09
Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res (1998) 3.01
Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res (2002) 2.98
Regulation of matrix metalloproteinase gene expression. J Cell Physiol (2007) 2.92
Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol (1999) 2.91
Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 2.89
Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet (1989) 2.86
Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci (2006) 2.81
Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science (1999) 2.62
Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation (2006) 2.58
Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res (1994) 2.46
Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res (2001) 2.38
Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res (2000) 2.36
Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci U S A (2002) 2.35
Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem (1992) 2.34
Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34
Matrix metalloproteinases and cardiovascular disease. Circ Res (1995) 2.27
Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation (2002) 2.25
Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol (1986) 2.20
Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation (2000) 2.01
Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics (2007) 1.98
Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest (2005) 1.94
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem (1996) 1.92
Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res (2002) 1.83
Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J (1993) 1.83
Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem (2001) 1.80
Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res (2005) 1.79
Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A (2001) 1.79
Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res (1999) 1.78
Vascular responses to alpha1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Arterioscler Thromb Vasc Biol (2006) 1.76
Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol (2007) 1.75
Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol (2003) 1.74
Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res (1997) 1.74
Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J (2004) 1.69
Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem (1986) 1.68
Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res (1983) 1.67
Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol (2006) 1.63
A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J Biol Chem (1992) 1.61
Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res (2006) 1.59
Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation (2005) 1.56
Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res (1998) 1.54
Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res (2000) 1.52
Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol (1999) 1.52
Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res (2005) 1.50
Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation (2004) 1.48
Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res (1997) 1.47
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci (1999) 1.44
Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.43
Extracellular matrix remodeling following myocardial injury. Ann Med (2003) 1.41
Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension (1999) 1.41
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res (2006) 1.40
Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem (2001) 1.40
Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch Biochem Biophys (1997) 1.38
Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol (2006) 1.36
Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett (1997) 1.36
TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation (2004) 1.36
Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood (2006) 1.31
Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation (2003) 1.31
A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res (1987) 1.31
Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res (2005) 1.30
Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res (2002) 1.30
Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol (2006) 1.29
Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res (2006) 1.29
A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J (2003) 1.29
Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation: modulation by PECAM-1 and MMP-2. J Cell Biol (2003) 1.28
Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev (2004) 1.27
Clinical studies with matrix metalloproteinase inhibitors. APMIS (1999) 1.26
Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res (2003) 1.26
Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J (2004) 1.25
Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J (2001) 1.25
Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J (2007) 1.23
Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res (2007) 1.23
Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis (2003) 1.22
Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J (1990) 1.21
Vascular smooth muscle alpha v beta 3 integrin mediates arteriolar vasodilation in response to RGD peptides. Circ Res (1996) 1.21
Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem (1993) 1.20
Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res (2006) 1.20
Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem (1995) 1.19
Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res (2000) 1.19
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J (2001) 1.18
Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep (2004) 1.18
Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res (2002) 1.15
Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res (2006) 1.14
Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ Res (1998) 1.12
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
Area characteristics and individual-level socioeconomic position indicators in three population-based epidemiologic studies. Ann Epidemiol (2001) 3.99
Localization of a short-term memory in Drosophila. Science (2000) 3.58
Prevalence and impact of caregiving: a detailed comparison between dementia and nondementia caregivers. Gerontologist (1999) 3.49
A life-span theory of control. Psychol Rev (1995) 3.43
The association of late-life depression and anxiety with physical disability: a review of the literature and prospectus for future research. Am J Geriatr Psychiatry (2001) 3.22
Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A (1991) 3.22
Gender differences in psychiatric morbidity among family caregivers: a review and analysis. Gerontologist (2000) 3.07
Self-reported causes of physical disability in older people: the Cardiovascular Health Study. CHS Collaborative Research Group. J Am Geriatr Soc (1994) 3.05
Morphine-tolerant longitudinal muscle strip from guinea-pig ileum. Br J Pharmacol (1973) 2.93
Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res (2000) 2.80
Group support interventions for women with breast cancer: who benefits from what? Health Psychol (2000) 2.38
Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med (1999) 2.21
Preventive health behaviors among spousal caregivers. Prev Med (1997) 2.17
Prenatal diagnosis of Smith-Lemli-Opitz syndrome, type II. Am J Med Genet (1994) 2.12
Negative and positive health effects of caring for a disabled spouse: longitudinal findings from the caregiver health effects study. Psychol Aging (2000) 2.09
Optimism and rehospitalization after coronary artery bypass graft surgery. Arch Intern Med (1999) 2.04
Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation (2000) 2.01
Long-term effects of educational and peer discussion group interventions on adjustment to breast cancer. Health Psychol (2001) 1.77
Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res (2000) 1.71
Language lateralization by Wada test and fMRI in 100 patients with epilepsy. Neurology (2003) 1.70
Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol (1998) 1.69
The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. Crit Care Med (2000) 1.68
Education and peer discussion group interventions and adjustment to breast cancer. Arch Gen Psychiatry (1999) 1.67
Management of obstructive sleep apnea in Europe. Sleep Med (2010) 1.56
Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol (1999) 1.55
Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med (1997) 1.54
Social support as a mediator in the relation between functional status and quality of life in older adults. Psychol Aging (1996) 1.51
Characterization of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta (1996) 1.50
The Wada test in Austrian, Dutch, German, and Swiss epilepsy centers from 2000 to 2005: a review of 1421 procedures. Epilepsy Behav (2008) 1.50
The bidirectional hydrogenase of Synechocystis sp. PCC 6803 works as an electron valve during photosynthesis. Arch Microbiol (2000) 1.49
Activity restriction and prior relationship history as contributors to mental health outcomes among middle-aged and older spousal caregivers. Health Psychol (1998) 1.48
Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res (1997) 1.47
Interventions for caregivers of patients with Alzheimer's disease: a review and analysis of content, process, and outcomes. Int J Aging Hum Dev (1996) 1.46
Impact of low copy repeats on the generation of balanced and unbalanced chromosomal aberrations in mental retardation. Cytogenet Genome Res (2006) 1.42
Judging outcomes in psychosocial interventions for dementia caregivers: the problem of treatment implementation. Gerontologist (2001) 1.40
Transcutaneous pCO2-monitoring for the evaluation of the anaerobic threshold. Comparison to lactate and ventilatory thresholds. Int J Sports Med (1993) 1.38
Association of pain and physical dependency with depression in physically ill middle-aged and elderly persons. Phys Ther (1988) 1.38
[The pathophysiology of myocardial circulation. I. Adaptation to myocardial ischemia (the "hibernating" myocardium)]. Dtsch Med Wochenschr (1994) 1.37
Effect of light on the NADPH-protochlorophyllide oxidoreductase of Arabidopsis thaliana. Plant Mol Biol (1991) 1.35
Long-term adjustment to physical disability: the role of social support, perceived control, and self-blame. J Pers Soc Psychol (1985) 1.35
Pain, activity restriction, and symptoms of depression among community-residing elderly adults. J Gerontol (1992) 1.34
Sequence analysis of an operon of a NAD(P)-reducing nickel hydrogenase from the cyanobacterium Synechocystis sp. PCC 6803 gives additional evidence for direct coupling of the enzyme to NAD(P)H-dehydrogenase (complex I). Biochim Biophys Acta (1996) 1.31
Gender bias in the measurement properties of the Center for Epidemiologic Studies Depression Scale (CES-D). Psychiatry Res (1993) 1.29
Spousal similarity in subjective well-being: the Cardiovascular Health Study. Psychol Aging (1996) 1.28
Spousal caregivers' activity restriction and depression: a model for changes over time. Soc Sci Med (1998) 1.28
Temporal lobe epilepsy with hippocampal sclerosis: predictors for long-term surgical outcome. Brain (2005) 1.25
Individual prediction of change in delayed recall of prose passages after left-sided anterior temporal lobectomy. Neurology (1997) 1.25
Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med (1998) 1.25
Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. Eur Respir J (2008) 1.24
Aspects of opiate dependence in the myenteric plexus of the guinea-pig. Life Sci (1976) 1.23
Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA (1997) 1.23
Activity restriction mediates the association between pain and depressed affect: a study of younger and older adult cancer patients. Psychol Aging (1995) 1.21
Characteristics and course of major depression in older primary care patients. Int J Psychiatry Med (1998) 1.21
Caregiving from the recipient's perspective: negative reactions to being helped. Health Psychol (1998) 1.21
Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. Bone Marrow Transplant (1993) 1.20
Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med (1997) 1.20
Comparative study on the effect of ethnicity on wisdom tooth eruption. Int J Legal Med (2007) 1.19
Uncoupling of contractile function from mitochondrial TCA cycle activity and MVO2 during reperfusion of ischemic hearts. Am J Physiol (1996) 1.17
Stability and change in older adults' social contact and social support: the Cardiovascular Health Study. J Gerontol B Psychol Sci Soc Sci (1999) 1.16
Electrically stimulated release of opiate-like material from the myenteric plexus of the guinea pig ileum. Eur J Pharmacol (1977) 1.16
Measurement of regional myocardial blood flow with multiple colored microspheres. Circulation (1991) 1.16
Physical illness and symptoms of depression among elderly outpatients. Psychol Aging (1992) 1.15
Correlates of performance-based measures of muscle function in the elderly: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci (1997) 1.13
Role of connexin 43 in ischemic preconditioning does not involve intercellular communication through gap junctions. J Mol Cell Cardiol (2004) 1.13
Relationship orientation, quality of prior relationship, and distress among caregivers of Alzheimer's patients. Psychol Aging (1990) 1.12
Selection bias and nonresponse to health promotion in older adults. Epidemiology (1994) 1.12
The European Sleep Apnoea Database (ESADA): report from 22 European sleep laboratories. Eur Respir J (2011) 1.11
Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am J Physiol Heart Circ Physiol (2000) 1.10
Infective endocarditis in the elderly in the era of transesophageal echocardiography: clinical features and prognosis compared with younger patients. Am J Med (1996) 1.09
Selective receptors for beta-endorphin on the rat vas deferens. Life Sci (1979) 1.09
Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res (1996) 1.09
Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol (1998) 1.09
Dental age estimation based on third molar eruption in First Nation people of Canada. J Forensic Odontostomatol (2010) 1.08
Social discomfort and depression in a sample of adults with leg amputations. Arch Phys Med Rehabil (1992) 1.08
On the central mediation of anorexigenic drug effects. Biochem Pharmacol (1973) 1.06
Studies of the chronological course of wisdom tooth eruption in a German population. J Forensic Leg Med (2008) 1.05
Coping with specific stressors in Alzheimer's disease caregiving. Gerontologist (1993) 1.05
Epileptic activity influences the speech organization in medial temporal lobe epilepsy. Brain (2003) 1.05
Effects of control and predictability on the physical and psychological well-being of the institutionalized aged. J Pers Soc Psychol (1976) 1.04
Inactivity of narcotic glucuronides as analgesics and on guinea-pig ileum. J Pharmacol Exp Ther (1972) 1.03
A comparison of primary stressors, secondary stressors, and depressive symptoms between elderly caregiving husbands and wives: the Caregiver Health Effects Study. Psychol Aging (2000) 1.03
Linking in situ bioassays and population dynamics of macroinvertebrates to assess agricultural contamination in streams of the Argentine pampa. Ecotoxicol Environ Saf (2004) 1.03
The influence of maternal exposure to volatile organic compounds on the cytokine secretion profile of neonatal T cells. Environ Toxicol (2002) 1.03
Study of age dependence of epiphyseal ossification of the hand skeleton. Int J Legal Med (2007) 1.02
The perspective of the patient with Alzheimer's disease: a neglected dimension of dementia research. Gerontologist (1993) 1.02
Research on physiological and physical concomitants of caregiving: where do we go from here? Ann Behav Med (1997) 1.02
Modifying repetitive verbalizations of community-dwelling patients with AD. Gerontologist (1997) 1.02
Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol (2001) 1.02
Studies of the chronological course of wisdom tooth eruption in a Japanese population. Forensic Sci Int (2007) 1.01
Predictors of in-home and out-of-home service use by family caregivers of Alzheimer's disease patients. J Aging Health (1993) 1.00
Effects of different antigenic microenvironments on the course of CD8+ T cell responses in vivo. Int Immunol (1996) 1.00
Caregiver cognitive status and potentially harmful caregiver behavior. Aging Ment Health (2006) 1.00
Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation (2001) 0.99
Endotoxin and ischemic preconditioning: TNF-alpha concentration and myocardial infarct development in rabbits. Am J Physiol (1999) 0.99
Feasibility of a dyadic intervention for management of osteoarthritis: a pilot study with older patients and their spousal caregivers. Aging Ment Health (2003) 0.99
Right hippocampal sclerosis is more common than left after febrile seizures. Neurology (2003) 0.99
Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts. Circulation (1999) 0.99
Highly specific opiate receptors for dynorphin-(1-13) in the mouse vas deferens. Eur J Pharmacol (1980) 0.99